Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes

Diabetes Care

Volumn 39, Issue 4, 2016, Pages 632-638

  Lomonaco, Romina ^a,b   Bril, Fernando ^a   Portillo Sanchez, Paola ^a   Ortiz Lopez, Carolina ^c   Orsak, Beverly ^c   Biernacki, Diane ^a   Lo, Margaret ^b   Suman, Amitabh ^d   Weber, Michelle H ^d   Cusi, Kenneth ^a,d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEMALE; GENDER; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PROTON NUCLEAR MAGNETIC RESONANCE; BLOOD; COHORT ANALYSIS; COMPLICATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; INSULIN RESISTANCE; MIDDLE AGED; SECRETION (PROCESS);

ADIPOSITY; ADULT; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TRIGLYCERIDES;

EID: 84962089316     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1876     Document Type: Article

References (42)

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273
2. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steato-hepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-788
3. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroen-terology 2011;140:124-131
4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395
5. Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase Levels. J Clin Endocrinol Metab 2015;100:2231-2238
6. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013;73:1-14
7. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepa-tology 2011;54:837-845
8. Bonnet F, Ducluzeau PH, Gastaldelli A, et al.; RISC Study Group. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 2011;60:1660-1667
9. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-1951
10. Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012; 35:873-878
11. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758
12. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010;105: 1567-1573
13. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009;16:141-149
14. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 2007; 7:175-180
15. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832
16. CusiK.Role of obesityand lipotoxicityin the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gas-troenterology 2012;142:711-725.e6
17. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-1397
18. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-689
19. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-1218
20. Maximos M, Bril F, Portillo Sanchez P, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hep-atology 2015;61:153-160
21. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2015;38(Suppl. 1):S8-S16
22. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
23. Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 2015;35:2139-2146
24. Perman WH, Balci NC, Akduman I. Review of magnetic resonance spectroscopy in the liver and the pancreas. Top Magn Reson Imaging 2009;20:89-97
25. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
26. Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. J Clin Endocrinol Metab 1996;81:4059-4067
27. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54: 344-353
28. Bril F, Maximos M, Portillo-Sanchez P, et al. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steato-hepatitis. J Hepatol 2015;62:405-411
29. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-213
30. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50:1087-1093
31. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133: 496-506
32. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474
33. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsuline-mia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014;59:2178-2187
34. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48: 634-642
35. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14: 804-810
36. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746
37. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008;135:122-130
38. Arulanandan A, Ang B, Bettencourt R, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; 13:1513-1520.e1
39. Bril F, Sninsky JJ, Baca AM, et al. Hepatic steatosis and insulin resistance, but not steato-hepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 2016;101: 644-652
40. Lomonaco R, Cusi K. Non-alcoholic fatty liver disease (NAFLD) in diabetes: distraction or impending disaster? In Evidence-Based Management of Diabetes. Shrewsbury, U.K., tfm publishing Ltd., 2012, p. 383-404
41. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-119
42. Williamson RM, Price JF, Glancy S, et al.; Edinburgh Type 2 Diabetes Study Investigators. Prevalenceofand risk factors for hepatic steatosis and nonalcoholic fatty liver diseaseinpeople with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139-1144